AU668873B2 - Antiviral liponucleosides: treatment of hepatitis B - Google Patents

Antiviral liponucleosides: treatment of hepatitis B

Info

Publication number
AU668873B2
AU668873B2 AU22268/92A AU2226892A AU668873B2 AU 668873 B2 AU668873 B2 AU 668873B2 AU 22268/92 A AU22268/92 A AU 22268/92A AU 2226892 A AU2226892 A AU 2226892A AU 668873 B2 AU668873 B2 AU 668873B2
Authority
AU
Australia
Prior art keywords
liponucleosides
antiviral
hepatitis
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
AU22268/92A
Other versions
AU2226892A (en
Inventor
Karl Y. Hostetler
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chimerix Corp
Original Assignee
Vestar Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US73027391A priority Critical
Priority to US730273 priority
Application filed by Vestar Inc filed Critical Vestar Inc
Priority to PCT/US1992/004856 priority patent/WO1993000910A1/en
Publication of AU2226892A publication Critical patent/AU2226892A/en
Assigned to VESTAR, INC. reassignment VESTAR, INC. Alteration of Name(s) of Applicant(s) under S113 Assignors: VICAL, INC.
Application granted granted Critical
Publication of AU668873B2 publication Critical patent/AU668873B2/en
Assigned to NEXSTAR PHARMACEUTICALS, INC. reassignment NEXSTAR PHARMACEUTICALS, INC. Alteration of Name(s) of Applicant(s) under S113 Assignors: VESTAR, INC.
Assigned to CHIMERIX, INC. reassignment CHIMERIX, INC. Alteration of Name(s) in Register under S187 Assignors: NEXSTAR PHARMACEUTICALS, INC.
Anticipated expiration legal-status Critical
Expired legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06Pyrimidine radicals
    • C07H19/10Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542Carboxylic acids, e.g. a fatty acid or an amino acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/548Phosphates or phosphonates, e.g. bone-seeking
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/127Liposomes
    • A61K9/1271Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16Purine radicals
    • C07H19/20Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • C07H19/207Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids the phosphoric or polyphosphoric acids being esterified by a further hydroxylic compound, e.g. flavine adenine dinucleotide or nicotinamide-adenine dinucleotide
AU22268/92A 1991-07-12 1992-06-03 Antiviral liponucleosides: treatment of hepatitis B Expired AU668873B2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
US73027391A true 1991-07-12 1991-07-12
US730273 1991-07-12
PCT/US1992/004856 WO1993000910A1 (en) 1991-07-12 1992-06-03 Antiviral liponucleosides: treatment of hepatitis b

Publications (2)

Publication Number Publication Date
AU2226892A AU2226892A (en) 1993-02-11
AU668873B2 true AU668873B2 (en) 1996-05-23

Family

ID=24934656

Family Applications (1)

Application Number Title Priority Date Filing Date
AU22268/92A Expired AU668873B2 (en) 1991-07-12 1992-06-03 Antiviral liponucleosides: treatment of hepatitis B

Country Status (5)

Country Link
EP (1) EP0594677A4 (en)
JP (1) JPH07500573A (en)
AU (1) AU668873B2 (en)
CA (1) CA2112803A1 (en)
WO (1) WO1993000910A1 (en)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL105244A (en) * 1993-03-31 2003-07-31 Dpharm Ltd Prodrugs with enhanced penetration into cells
US5484911A (en) * 1993-04-01 1996-01-16 Health Research, Inc. Nucleoside 5'-diphosphate conjugates of ether lipids
DE4321978A1 (en) * 1993-07-01 1995-01-12 Boehringer Mannheim Gmbh Liponucleotides of deoxynucleosides, their production and their use as antiviral drugs
US20020120130A1 (en) 1993-09-10 2002-08-29 Gilles Gosselin 2' or 3' -deoxy and 2', 3' -dideoxy-beta-L-pentofuranonucleo-side compounds, method of preparation and application in therapy, especially as anti- viral agents
US7135584B2 (en) 1995-08-07 2006-11-14 Wake Forest University Lipid analogs for treating viral infections
JP4259611B2 (en) 1994-08-29 2009-04-30 ウェイク フォレスト ユニバーシティWake Forest University Lipid analogues for treating viral infections
US6413949B1 (en) * 1995-06-07 2002-07-02 D-Pharm, Ltd. Prodrugs with enhanced penetration into cells
US6313106B1 (en) 1995-06-07 2001-11-06 D-Pharm Ltd. Phospholipid derivatives of valproic acid and mixtures thereof
AU2003201382B8 (en) * 1995-06-07 2010-04-29 Centre National De La Recherche Scientifique Nucleosides with anti-hepatitis B virus activity
EP1655033A1 (en) 1995-06-07 2006-05-10 Emory University Nucleosides with anti-hepatitis B virus activity
DE69933860T2 (en) 1998-02-25 2007-05-31 Choi, Yongseok 2'-fluoronukleoside
DK1104436T3 (en) 1998-08-10 2006-04-03 Centre Nat Rech Scient Beta-L-2'-deoxy nucleosides for the treatment of hepatitis B virus
US6444652B1 (en) 1998-08-10 2002-09-03 Novirio Pharmaceuticals Limited β-L-2'-deoxy-nucleosides for the treatment of hepatitis B
US6528515B1 (en) 1998-11-02 2003-03-04 Triangle Pharmaceuticals, Inc. Combination therapy to treat hepatitis B virus
IL127143D0 (en) 1998-11-19 1999-09-22 Dpharm Ltd Phospholipid terivatives of non-steroidal anti inflammatory drugs
IL131887D0 (en) 1999-09-14 2001-03-19 Dpharm Ltd Phospholipid prodrugs of anti-proliferative drugs
US7309696B2 (en) 2000-10-19 2007-12-18 Wake Forest University Compositions and methods for targeting cancer cells
US7026469B2 (en) 2000-10-19 2006-04-11 Wake Forest University School Of Medicine Compositions and methods of double-targeting virus infections and cancer cells
CA2405502A1 (en) 2000-03-29 2001-10-04 Georgetown University Method of treating hepatitis delta viral infection
US6761901B1 (en) 2000-05-02 2004-07-13 Enzrel Inc. Liposome drug delivery
MY164523A (en) 2000-05-23 2017-12-29 Idenix (Cayman) Ltd Methods and compositions for treating hepatitis c virus
US6787526B1 (en) 2000-05-26 2004-09-07 Idenix Pharmaceuticals, Inc. Methods of treating hepatitis delta virus infection with β-L-2′-deoxy-nucleosides
IL153020D0 (en) 2000-05-26 2003-06-24 Idenix Cayman Ltd Methods and compositions for treating flaviviruses and pestiviruses
US6875751B2 (en) 2000-06-15 2005-04-05 Idenix Pharmaceuticals, Inc. 3′-prodrugs of 2′-deoxy-β-L-nucleosides
US6689760B1 (en) 2000-07-10 2004-02-10 Enzrel Inc. Anti-mycobacterial compositions
US6455073B1 (en) 2000-07-10 2002-09-24 Enzrel, Inc. Covalent microparticle-drug conjugates for biological targeting
KR101005299B1 (en) 2000-10-18 2011-01-04 파마셋 인코포레이티드 Modified nucleosides for treatment of viral infections and abnormal cellular proliferation
JP5105689B2 (en) 2001-03-01 2012-12-26 ギリード・サイエンシズ・インコーポレーテッド Polymorphic and other crystalline forms of cis-FTC
US7551837B2 (en) 2001-08-31 2009-06-23 Thomson Licensing Sequence counter for an audio visual stream
WO2003059288A2 (en) 2002-01-09 2003-07-24 Enzrel, Inc. Liposome drug delivery of polycyclic, aromatic, antioxidant or anti-inflammatory compounds
US7608600B2 (en) 2002-06-28 2009-10-27 Idenix Pharmaceuticals, Inc. Modified 2′ and 3′-nucleoside prodrugs for treating Flaviviridae infections
PT1523489E (en) 2002-06-28 2014-06-24 Centre Nat Rech Scient Modified 2' and 3' -nucleoside produgs for treating flaviridae infections
KR20050035194A (en) 2002-06-28 2005-04-15 이데닉스 (케이만) 리미티드 2'-c-methyl-3'-o-l-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections
TWI244393B (en) 2002-08-06 2005-12-01 Idenix Pharmaceuticals Inc Crystalline and amorphous forms of beta-L-2'-deoxythymidine
HUE027522T2 (en) 2002-09-13 2016-11-28 Novartis Ag Beta-l-2'-deoxynucleosides for use in the treatment of resistant hbv strains
PL377342A1 (en) 2002-11-15 2006-01-23 Idenix (Cayman) Limited 2'-branched nucleosides and flaviviridae mutation
EP3521297A1 (en) 2003-05-30 2019-08-07 Gilead Pharmasset LLC Modified fluorinated nucleoside analogues
US20050075309A1 (en) 2003-07-25 2005-04-07 Richard Storer Purine nucleoside analogues for treating Flaviviridae including hepatitis C
MXPA06011219A (en) 2004-03-29 2007-05-08 Univ South Florida Effective treatment of tumors and cancer with triciribine and related compounds.
KR101177590B1 (en) 2004-09-14 2012-08-27 파마셋 인코포레이티드 Preparation of 2'-fluoro-2'-alkyl-substituted or other optionally substituted ribofuranosyl pyrimidines and purines and their derivatives
AU2006294807B2 (en) 2005-09-26 2013-01-17 Gilead Pharmasset Llc Modified 4'-nucleosides as antiviral agents
US8895531B2 (en) 2006-03-23 2014-11-25 Rfs Pharma Llc 2′-fluoronucleoside phosphonates as antiviral agents
US7964580B2 (en) 2007-03-30 2011-06-21 Pharmasset, Inc. Nucleoside phosphoramidate prodrugs
US8415321B2 (en) 2008-04-15 2013-04-09 Raymond F. Schinazi Nucleoside derivatives for treatment of Caliciviridae infections, including Norovirus infections
EA019341B1 (en) 2008-12-23 2014-02-28 Джилид Фармассет, Ллс. Nucleoside phosphoramidates
TW201031675A (en) 2008-12-23 2010-09-01 Pharmasset Inc Synthesis of purine nucleosides
TWI583692B (en) 2009-05-20 2017-05-21 基利法瑪席特有限責任公司 Nucleoside phosphoramidates
US8618076B2 (en) 2009-05-20 2013-12-31 Gilead Pharmasset Llc Nucleoside phosphoramidates
AP201206535A0 (en) 2010-03-31 2012-10-31 Gilead Pharmasset Llc Stereoselective synthesis of phosphorous containing actives
EP3042910B1 (en) 2010-11-30 2019-01-09 Gilead Pharmasset LLC 2'-spiro-nucleosides for use in the therapy of hepatitis c
AU2012308295B2 (en) 2011-09-16 2017-10-26 Gilead Pharmasset Llc Methods for treating HCV
US8889159B2 (en) 2011-11-29 2014-11-18 Gilead Pharmasset Llc Compositions and methods for treating hepatitis C virus
AU2012345732B2 (en) 2011-11-30 2016-07-14 Emory University Antiviral JAK inhibitors useful in treating or preventing retroviral and other viral infections
JP2015508418A (en) 2013-01-31 2015-03-19 ギリアド ファーマセット エルエルシー Combinatorial formulation of two antiviral compounds

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU647164B2 (en) * 1990-05-29 1994-03-17 Nexstar Pharmaceuticals, Inc. Synthesis of glycerol di- and triphosphate derivatives
AU660417B2 (en) * 1990-06-15 1995-06-29 University Of North Carolina At Chapel Hill, The Ether lipid-nucleoside covalent conjugates

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4291024A (en) * 1978-04-10 1981-09-22 Turcotte Joseph G Cytotoxic liponucleotide analogs
US5223263A (en) * 1988-07-07 1993-06-29 Vical, Inc. Liponucleotide-containing liposomes
AT131825T (en) * 1990-06-13 1996-01-15 Arnold Glazier Phosphorylated prodrugs

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU647164B2 (en) * 1990-05-29 1994-03-17 Nexstar Pharmaceuticals, Inc. Synthesis of glycerol di- and triphosphate derivatives
AU660417B2 (en) * 1990-06-15 1995-06-29 University Of North Carolina At Chapel Hill, The Ether lipid-nucleoside covalent conjugates

Also Published As

Publication number Publication date
CA2112803A1 (en) 1993-01-21
JPH07500573A (en) 1995-01-19
EP0594677A4 (en) 1997-09-17
AU2226892A (en) 1993-02-11
EP0594677A1 (en) 1994-05-04
WO1993000910A1 (en) 1993-01-21

Similar Documents

Publication Publication Date Title
AU651593B2 (en) Antisense inhibitors of the human immunodeficiency virus
AU665533B2 (en) Treatment of material
AU672151B2 (en) Diaper article
DE69132332D1 (en) Hepatitis c-virus-epitope
AU675417B2 (en) Treatment of periodontal disease with alendronate
AU1219292A (en) Inhaler
GB2280606B (en) Physical forms of benzenesulphonamides
AU2014595A (en) Quick-cooking oven
HK56897A (en) Benzocyclobutyl-or indanyl-alkyl-amino-alkyl substituted 3-benzazepin-2-ones useful in the treatment of cardiovascular diseases
PL309398A1 (en) Interferon containing therapeutic composition
AU677367B2 (en) Antiviral agent
AU668860B2 (en) Antiviral nucleoside combination
AU635148B2 (en) Dilatation catheter
PL313619A1 (en) Derivatives of piperydine
PL310443A1 (en) Derivatives of pyrolo-pyridine
AU2373692A (en) Swimsuit
GB9122318D0 (en) Treatment of elongate members
AU1153492A (en) Use of 1,3-oxathiolane nucleoside analogues in the treatment of hepatitis b
GB8706313D0 (en) Treatment & prevention of viral infections
ZA9204772B (en) Delayed therapy
AU2421192A (en) Inhaler
IE65969B1 (en) Use of stearidonic acid
GB9204015D0 (en) Therapeutic nucleosides
AU644095B2 (en) Antiviral compounds
HK1005435A1 (en) Purification of solutions

Legal Events

Date Code Title Description
PC Assignment registered

Owner name: CHIMERIX, INC.

Free format text: FORMER OWNER WAS: NEXSTAR PHARMACEUTICALS, INC.